GLP-1s for Sleep Apnea: Reading the SURMOUNT-OSA Data

Obstructive sleep apnea and obesity travel together. Excess weight, particularly around the neck and upper airway, contributes to the airway collapse that defines the condition. So it’s a logical question: if a drug drives substantial weight loss, does it also improve sleep apnea? The SURMOUNT-OSA trial set out to test exactly that with tirzepatide — and the answer was more than a shrug.

What the trial measured

The standard metric for sleep apnea severity is the apnea-hypopnea index (AHI) — roughly, how many times per hour breathing is interrupted during sleep. SURMOUNT-OSA was actually two phase 3 trials (469 participants total) of people with obesity and moderate-to-severe obstructive sleep apnea, published in The New England Journal of Medicine in 2024. Trial 1 enrolled people not using positive airway pressure (PAP) therapy; trial 2 enrolled those who were. Both tested tirzepatide (10 mg or 15 mg) against placebo over 52 weeks.

The effect was large in both:

Outcome (week 52)	Trial 1	Trial 2
AHI change, tirzepatide	−25.3 events/hr	−29.3 events/hr
AHI change, placebo	−5.3 events/hr	−5.5 events/hr
Treatment difference	−20.0 (P<0.001)	−23.8 (P<0.001)
Met disease-resolution criteria	42.2% vs 15.9%	50.2% vs 14.3%
Body-weight change	−17.7% vs −1.6%	−19.6% vs −2.3%

The effect was substantial enough that tirzepatide (as Zepbound) became the first drug FDA-approved for moderate-to-severe OSA in adults with obesity.

The honest framing: this is a real, clinically relevant signal — roughly 20-24 fewer apnea events per hour than placebo. But the benefit travels through weight loss; it’s not evidence the drug treats the airway directly.

Why this matters beyond apnea

The result is a clean illustration of how interconnected metabolic disease is. Sleep apnea isn’t only a breathing problem — it’s tightly linked to weight, and addressing the weight addresses part of the breathing. That has implications for how clinicians think about obesity-driven conditions more broadly.

Worth keeping in view

• The benefit is mediated by weight loss, so it likely depends on sustaining that loss.
• This doesn’t replace established care like CPAP for everyone; it’s an additional tool in appropriate patients.
• Individual response varies, and apnea has causes beyond weight.

The takeaway

SURMOUNT-OSA showed tirzepatide cutting the apnea-hypopnea index by roughly 20 to 24 events per hour beyond placebo, with about 42-50% of treated participants meeting disease-resolution criteria — a genuinely notable result that reflects how deeply obesity and apnea are entwined, and one that earned FDA approval. The honest caveat is that the mechanism runs through weight loss, so durability depends on maintaining it, and it complements rather than wholesale replaces existing treatment like CPAP. Still, it’s a strong example of metabolic medicine reaching beyond the scale.

Sources

• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (New England Journal of Medicine, 2024)